SEQUENCE LISTING

<110> NATIONAL UNIVERSITY OF SINGAPORE
LIM, YOON-PIN

<120> Novel Cancer Target and Biomarker

<130> AY/YF/ak/2011.5815

<150> SG201006302-2
<151> 2010-08-30

<160> 11

<170> PatentIn version 3.5

<210> 1
<211> 261
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (168)..(170)
<223> polyproline-tyrosine motif

<220>
<221> MOD_RES
<222> (192)..(192)
<223> PHOSPHORYLATION

<220>
<221> MISC_FEATURE
<222> (197)..(200)
<223> polyproline-tyrosine motif

<220>
<221> MOD_RES
<222> (231)..(231)
<223> PHOSPHORYLATION

<220>
<221> MISC_FEATURE
<222> (250)..(253)
<223> polyproline-tyrosine motif

<400> 1

Met Ala Leu Asn Lys Asn His Ser Glu Gly Gly Gly Val Ile Val Asn
1 5 10 15

Asn Thr Glu Ser Ile Leu Met Ser Tyr Asp His Val Glu Leu Thr Phe
20 25 30

Asn Asp Met Lys Asn Val Pro Glu Ala Phe Lys Gly Thr Lys Lys Gly
35 40 45

Thr Val Tyr Leu Thr Pro Tyr Arg Val Ile Phe Leu Ser Lys Gly Lys
50 55 60

Asp Ala Met Gln Ser Phe Met Met Pro Phe Tyr Leu Met Lys Asp Cys
65 70 75 80

Glu Ile Lys Gln Pro Val Phe Gly Ala Asn Tyr Ile Lys Gly Thr Val
85 90 95

Lys Ala Glu Ala Gly Gly Gly Trp Glu Gly Ser Ala Ser Tyr Lys Leu

100 105 110

Thr Phe Thr Ala Gly Gly Ala Ile Glu Phe Gly Gln Arg Met Leu Gln
115 120 125

Val Ala Ser Gln Ala Ser Arg Gly Glu Val Pro Ser Gly Ala Tyr Gly
130 135 140

Tyr Ser Tyr Met Pro Ser Gly Ala Tyr Val Tyr Pro Pro Pro Val Ala
145 150 155 160

Asn Gly Met Tyr Pro Cys Pro Pro Gly Tyr Pro Tyr Pro Pro Pro Pro
165 170 175

Pro Glu Phe Tyr Pro Gly Pro Pro Met Met Asp Gly Ala Met Gly Tyr
180 185 190

Val Gln Pro Pro Pro Pro Pro Tyr Pro Gly Pro Met Glu Pro Pro Val
195 200 205

Ser Gly Pro Asp Val Pro Ser Thr Pro Ala Ala Glu Ala Lys Ala Ala
210 215 220

Glu Ala Ala Ala Ser Ala Tyr Tyr Asn Pro Gly Asn Pro His Asn Val
225 230 235 240

Tyr Met Pro Thr Ser Gln Pro Pro Pro Pro Pro Tyr Tyr Pro Pro Glu
245 250 255

Asp Lys Lys Thr Gln
260

<210> 2
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> siRNA

<400> 2
agcauccgcu guccgaacuc aaugg 25

<210> 3
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide derived from human WBP2 protein

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> a nuclear localization signal

<400> 3

Xaa Pro Pro Gly Tyr Pro Pro Pro Tyr Pro Pro Pro Tyr
1 5 10

<210> 4
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide derived from human WBP2 protein

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> a nuclear localization signal

<400> 4

Pro Pro Gly Tyr Pro Pro Pro Tyr Pro Pro Pro Tyr Xaa
1 5 10

<210> 5
<211> 41
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide derived from human WBP2 protein

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> a nuclear localization signal

<400> 5

Xaa Tyr Val Gln Pro Pro Pro Pro Pro Tyr Pro Gly Pro Met Glu Pro
1 5 10 15

Pro Val Ser Gly Pro Asp Val Pro Ser Thr Pro Ala Ala Glu Ala Lys
20 25 30

Ala Ala Glu Ala Ala Ala Ser Ala Tyr
35 40

<210> 6
<211> 41
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide derived from human WBP2 protein

<220>
<221> MISC_FEATURE
<222> (41)..(41)
<223> a nuclear localization signal

<400> 6

Tyr Val Gln Pro Pro Pro Pro Pro Tyr Pro Gly Pro Met Glu Pro Pro
1 5 10 15

Val Ser Gly Pro Asp Val Pro Ser Thr Pro Ala Ala Glu Ala Lys Ala
20 25 30

Ala Glu Ala Ala Ala Ser Ala Tyr Xaa

35 40

<210> 7
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> antigen from a section of the human WBP2 protein sequence No. 1 used for antibody production

<400> 7

Asn Asp Met Lys Asn Val Pro Glu Ala Phe Lys Gly Thr Lys Lys Gly
1 5 10 15

Thr

<210> 8
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> siRNA sequence from Invitrogen

<400> 8
uucuccuaca agaauauuag cagcc 25

<210> 9
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> siRNA sequence from Invitrogen

<400> 9
gccucucagu gucugacuuc gacaa 25

<210> 10
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> siRNA sequence from Invitrogen

<400> 10
cguacgcgga auacuucga 19

<210> 11
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> siRNA sequence from Invitrogen

<400> 11
caggaacuag cauuguggga cauua 25